Ajooni Biotech Ltd
AJOONIAjooni Biotech Ltd
AJOONI
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 60.59 | 3.18 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ajooni Biotech Pvt Ltd is a manufacturer of medicinals and botanicals
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 13.23 | 28.58 | 42.59 | 40.06 | 40.09 | 51.06 | 74.08 | 74.78 | 82.30 | 86.93 | ||||||||||
Raw Materials | 11.02 | 24.42 | 37.55 | 36.46 | 34.94 | 43.36 | 63.91 | 66.12 | 69.86 | 82.24 | ||||||||||
| Power & Fuel Cost | 0.15 | 0.00 | 0.30 | 0.57 | 0.62 | 1.05 | 0.92 | 0.69 | 0.82 | |||||||||||
| Employee Cost | 0.43 | 0.59 | 0.88 | 0.72 | 1.12 | 1.15 | 1.48 | 1.76 | 1.80 | |||||||||||
| Selling & Administrative Expenses | 1.32 | 0.00 | 2.22 | 1.12 | 1.91 | 3.74 | 3.51 | 2.91 | 3.96 | |||||||||||
| Operating & Other expenses | 0.08 | 2.86 | 0.49 | 0.16 | 0.21 | 0.10 | 1.14 | 0.24 | 1.44 | |||||||||||
EBITDA | 0.23 | 0.71 | 1.15 | 1.03 | 1.29 | 1.66 | 3.12 | 3.06 | 4.42 | 4.69 | ||||||||||
| Depreciation/Amortization | 0.07 | 0.19 | 0.31 | 0.44 | 0.49 | 0.58 | 1.11 | 1.00 | 0.87 | 0.88 | ||||||||||
| PBIT | 0.16 | 0.52 | 0.84 | 0.59 | 0.80 | 1.08 | 2.01 | 2.06 | 3.55 | 3.81 | ||||||||||
| Interest & Other Items | 0.02 | 0.14 | 0.35 | 0.11 | 0.33 | 0.58 | 0.54 | 0.48 | 0.56 | 0.57 | ||||||||||
| PBT | 0.14 | 0.38 | 0.49 | 0.48 | 0.47 | 0.50 | 1.47 | 1.58 | 2.99 | 3.24 | ||||||||||
| Taxes & Other Items | 0.04 | 0.11 | 0.10 | 0.07 | 0.14 | 0.13 | 0.41 | 0.45 | 0.84 | 1.00 | ||||||||||
| Net Income | 0.10 | 0.27 | 0.39 | 0.41 | 0.33 | 0.37 | 1.06 | 1.13 | 2.15 | 2.24 | ||||||||||
| EPS | 0.04 | 0.10 | 0.03 | 0.02 | 0.01 | 0.01 | 0.05 | 0.14 | 0.22 | 0.23 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Ajooni Biotech Ltd | 63.13 | 3.18 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare AJOONI with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 5.78%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
AJOONI has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAjooni Biotech will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Ajooni Biotech announced that the 14th Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live
Ajooni Biotech will hold a meeting of the Board of Directors of the Company on 16 August 2024.Powered by Capital Market - Live
Net profit of Ajooni Biotech rose 17.50% to Rs 0.47 crore in the quarter ended June 2024 as against Rs 0.40 crore during the previous quarter ended June 2023. Sales rose 22.19% to Rs 25.66 crore in the quarter ended June 2024 as against Rs 21.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales25.6621.00 22 OPM %3.743.14 - PBDT0.850.60 42 PBT0.630.39 62 NP0.470.40 18 Powered by Capital Market - Live
Ajooni Biotech will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Ajooni Biotech Eyes Additional Rs 200 Crore Revenue from Commercial Production of Moringa by FY2025-26 - News18
Ajooni Biotech Standalone June 2023 Net Sales at Rs 21.00 crore, up 70.61% Y-o-Y
Ajooni Biotech Ltd launches pilot project in Rajasthan for exploring potential in MORINGA farming
Ajooni Biotech rights issue to raise Rs 29 cr open on Wednesday
Ajooni Biotech Standalone September 2022 Net Sales at Rs 10.29 crore, down 44.04% Y-o-Y
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.49%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.02%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 39.29%, vs industry avg of 15.28%